Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Table 3 Immunologic responses to the pneumococcal and influenza vaccines at Day 28 post-vaccination

	Pneumococcal vaccine (n = 113)	Influenza vaccine (n = 186)
Primary definition
Patients without protective antibody levels at baseline^a
n/N (%)	34/46 (73.9)	73/119 (61.3)
95 % CI	61.2, 86.6	52.6, 70.1
Patients with protective antibody levels at baseline
n/N (%)	28/66 (42.4)	18/65 (27.7)
95 % CI	30.5, 54.3	16.8, 38.6
Total
n/N (%)	62/112 (55.4)	91/184 (49.5)
95 % CI	46.2, 64.6	42.2, 56.7
Conservative definition
Patients without protective antibody levels at baseline^a
n/N (%)	16/46 (34.8)	N/A
95 % CI	21.0, 48.5	N/A
Patients with protective antibody levels at baseline
n/N (%)	8/65 (12.3)	N/A
95 % CI	4.3, 20.3	N/A
Total
n/N (%)	24/111 (21.6)	N/A
95 % CI	14.0, 29.3	N/A

CI confidence interval, N/A not applicable
^aPrimary endpoint. Patients with >42 days between the pre- and post-vaccination sample dates were excluded from the analysis. One patient from the pneumococcal study had >42 days between pre- and post-vaccination samples (57 days) and did not have protective antibody levels at baseline; the patient did not achieve an immunologic response post-vaccination. Two patients from the influenza study had >42 days between pre- and post-vaccination sample (46 days: patient did not have protective antibodies at baseline and did not achieve an immunologic response post-vaccination; 43 days: patient did not have protective antibodies at baseline and achieved immunologic response post-vaccination)

ISSN: 1471-2474